- TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS
-
This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.
- -
-
-
- HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION
-
This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
- -
-
Page/Page column 154
(2019/07/20)
-
- COMPOUNDS AND THERAPEUTIC USES THEREOF
-
The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.
- -
-
Page/Page column 101
(2010/11/03)
-
- PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
-
The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N-(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and Rs
- -
-
Page/Page column 101-102
(2009/05/29)
-
- 2, 4-DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
-
The present invention encompasses compounds of general formula (1) wherein Q and R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the
- -
-
Page/Page column 23
(2008/06/13)
-
- COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION
-
The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
- -
-
Page/Page column 70
(2008/06/13)
-
- DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES
-
The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.
- -
-
Page/Page column 70
(2008/06/13)
-
- New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments
-
Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, Rsup
- -
-
Page/Page column 14
(2008/06/13)
-
- 2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS
-
The invention relates to compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1, and R3 are defined as indicated in claim 1. Said compounds are used for the treatment of diseases characterized by excessive or anomalous cell proliferation. Also disclosed is the use of the inventive compounds for producing a medicament having said properties.
- -
-
Page/Page column 45-46
(2008/06/13)
-
- PI3 KINASES
-
The invention relates to the novel compounds of formula (1), which, due to their pharmaceutical effect as PI3 kinase modulators, are suitable for use in the therapy and treatment of inflammatory or allergic diseases. Examples of these diseases are inflammatory and allergic respiratory diseases, inflammatory diseases of the gastro-intestinal system and of the locomotor apparatus, inflammatory and allergic skin diseases, inflammatory ophthalmic diseases, diseases of the nasal mucosa, inflammatory or allergic autoimmune reactive conditions, or renal inflammations.
- -
-
Page/Page column 123
(2008/06/13)
-
- New pteridinones as PLK inhibitors
-
Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the trea
- -
-
Page/Page column 9; 12
(2008/06/13)
-
- Storage stable perfusion solution for dihydropteridinones
-
Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.
- -
-
Page/Page column 19
(2008/06/13)
-
- PTERIDINONES USED AS PLK (POLO LIKE KINASE) INHIBITORS
-
The invention relates to compounds of general formula (1), wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3, and R4 are defined as indicated in claim 1. Said
- -
-
Page/Page column 26; 33
(2010/10/20)
-
- Chemokine receptor binding heterocyclic compounds with enhanced efficacy
-
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
- -
-
-
- New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
-
The present invention relates to new dihydropteridinones of general formula (I) wherein the groups L and R1- R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropterid
- -
-
Page/Page column 14
(2010/02/08)
-